HK1040924A1 - 降膽固醇劑的應用 - Google Patents

降膽固醇劑的應用 Download PDF

Info

Publication number
HK1040924A1
HK1040924A1 HK02102713.0A HK02102713A HK1040924A1 HK 1040924 A1 HK1040924 A1 HK 1040924A1 HK 02102713 A HK02102713 A HK 02102713A HK 1040924 A1 HK1040924 A1 HK 1040924A1
Authority
HK
Hong Kong
Prior art keywords
compound
dosages
cholesterol
lowering agent
lipid
Prior art date
Application number
HK02102713.0A
Other languages
English (en)
Chinese (zh)
Inventor
Raza Ali
Original Assignee
阿斯特拉曾尼卡有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1040924(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902590.0A external-priority patent/GB9902590D0/en
Priority claimed from GBGB9921062.7A external-priority patent/GB9921062D0/en
Application filed by 阿斯特拉曾尼卡有限公司 filed Critical 阿斯特拉曾尼卡有限公司
Publication of HK1040924A1 publication Critical patent/HK1040924A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK02102713.0A 1999-02-06 2000-02-01 降膽固醇劑的應用 HK1040924A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9902590.0A GB9902590D0 (en) 1999-02-06 1999-02-06 Use of cholesterol-lowering agent
GB9902590.0 1999-02-06
GBGB9921062.7A GB9921062D0 (en) 1999-09-08 1999-09-08 Use of cholestrol-lowering agent
GB9921062.7 1999-09-08
PCT/GB2000/000285 WO2000045819A1 (en) 1999-02-06 2000-02-01 Use of cholesterol-lowering agent

Publications (1)

Publication Number Publication Date
HK1040924A1 true HK1040924A1 (zh) 2002-06-28

Family

ID=26315084

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102713.0A HK1040924A1 (zh) 1999-02-06 2000-02-01 降膽固醇劑的應用

Country Status (22)

Country Link
EP (1) EP1150679A1 (https=)
JP (2) JP2002536333A (https=)
KR (1) KR100699287B1 (https=)
CN (1) CN1347320A (https=)
AR (1) AR022462A1 (https=)
AU (1) AU769897B2 (https=)
BR (1) BR0007991A (https=)
CA (1) CA2358641A1 (https=)
CZ (1) CZ20012631A3 (https=)
EE (1) EE04659B1 (https=)
HK (1) HK1040924A1 (https=)
HU (1) HUP0105019A3 (https=)
ID (1) ID30131A (https=)
IL (1) IL144662A0 (https=)
IS (1) IS5996A (https=)
MY (1) MY136382A (https=)
NO (1) NO319827B1 (https=)
NZ (1) NZ512681A (https=)
PL (1) PL349137A1 (https=)
SK (1) SK11112001A3 (https=)
TR (1) TR200102236T2 (https=)
WO (1) WO2000045819A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
SE0103509D0 (sv) * 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2007142581A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Combination product for the treatment or prevention of dyslipidaemia
CA2689523A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
EP2166847B1 (en) 2007-06-20 2014-11-19 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
WO2008156715A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Cetp inhibitors derived from benzoxazole arylamides
EP2216095A1 (en) * 2009-01-27 2010-08-11 Koninklijke Philips Electronics N.V. Microfluidic device for full blood count

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260446A (en) * 1989-12-22 1993-11-09 Basf Aktiengesellschaft Aminothiazoles
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体

Also Published As

Publication number Publication date
KR20010089631A (ko) 2001-10-06
AR022462A1 (es) 2002-09-04
AU2305100A (en) 2000-08-25
NO20013810D0 (no) 2001-08-03
MY136382A (en) 2008-09-30
NO20013810L (no) 2001-10-03
EE200100404A (et) 2002-10-15
ID30131A (id) 2001-11-08
HUP0105019A2 (hu) 2002-05-29
WO2000045819A1 (en) 2000-08-10
KR100699287B1 (ko) 2007-03-26
IL144662A0 (en) 2002-05-23
CA2358641A1 (en) 2000-08-10
NZ512681A (en) 2003-12-19
AU769897B2 (en) 2004-02-05
CN1347320A (zh) 2002-05-01
JP2011137023A (ja) 2011-07-14
HUP0105019A3 (en) 2003-02-28
EE04659B1 (et) 2006-08-15
SK11112001A3 (sk) 2002-02-05
TR200102236T2 (tr) 2001-12-21
BR0007991A (pt) 2001-11-06
CZ20012631A3 (cs) 2001-10-17
JP2002536333A (ja) 2002-10-29
EP1150679A1 (en) 2001-11-07
PL349137A1 (en) 2002-07-01
NO319827B1 (no) 2005-09-19
IS5996A (is) 2001-07-10

Similar Documents

Publication Publication Date Title
CA2315141A1 (en) Pharmaceutical compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof
IL155919A (en) (e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl ( methylsulfonyl) amino] pyrimidin - 5 - yl] (3r, 5s) - dihydroxyhept - 6 - enoic acid, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of heterozygous familial hypercholesterolemia
JP2006508953A5 (https=)
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
LT2001119A (en) Pharmaceutical formulations comprising intranasal morphine and use thereof
NZ564167A (en) Dispersible tablet comprising 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-benzenesulfonamide (bosutan)
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
HK1040924A1 (zh) 降膽固醇劑的應用
EP1256344A4 (en) REMEDIES FOR ENDOTHELIN-INDUCED DISEASES
JP2002536333A5 (https=)
NO20063277L (no) Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav
WO2010030201A3 (en) Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid
WO2007071357A3 (en) Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
BR0207271A (pt) Composição farmacêutica
TH68542A (th) การใช้สารลดโคเลสเตียรอล
TH88724B (th) การรักษา
TH88724A (th) การรักษา
WO2002028380A3 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
PL375503A1 (en) Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor
BR0013921A (pt) Composições farmacêuticas para tratamento de psorìase
RU2001124663A (ru) Применение средства, снижающего содержание холестерина
WO2002072016A3 (en) Method of preventing adhesions with ifn-¿y?
MY145885A (en) Controlled release formulations for oral administration
HRP20110563T1 (en) Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile